Back

A historical perspective: why we opted triple therapy for so long and what made us change our mind.

31 August 2020 (12:00 - 12:11)
Organised by:
Congress Presentation Part of: Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)

3 More presentations in this session

Presentation thumbnail
Dual versus triple antithrombotic therapy, does trial design make the difference?
Professor R. Storey (Sheffield, GB)
Slides Video
Presentation thumbnail
Triple therapy: still an option?
Professor K. Huber (Vienna, AT)
Slides Video
Presentation thumbnail
Dual versus triple antithrombotic therapy - The fine art of personalised medicine.
Professor R. De Caterina (Pisa, IT)
Slides Video

Access the full session

Session thumbnail
Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting

The Event

Event poster

ESC Congress 2020

31 August 2020 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Portuguese experience with dual and triple therapy in atrial fibrillation and acute coronary syndrome patients
29 June 2021
thumbnail
Congress Presentation
Conclusion.
28 August 2022
thumbnail
Congress Presentation
Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: Insights from the randomised controlled TRITON study
29 August 2020
thumbnail
Congress Presentation
Eligibility for simultaneous initiation of the four pharmacological pillars of heart failure with reduced ejection fraction at discharge
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources